FDA Brief

Warning letters Food

FDA warning letter to

Young Living Essential Oils Corporate

High riskIssued Jun 10, 2022Posted Jul 19, 2022Office of Human and Animal Food Operations – West Division 4

FDA warned Young Living that consultants' social media and website claims made its essential oil, Ningxia, and CBD products unapproved and misbranded drugs.

What happened

In May 2022, FDA reviewed Young Living's websites and social media accounts for several paid consultants. FDA found posts and pages promoting essential oils, Vitality products, Ningxia, and Nature's Ultra CBD products for treating or preventing diseases such as infections, allergies, cancer, depression, and Parkinson's disease.

What FDA found

  1. FDA says the products are drugs because they are promoted to cure, mitigate, treat, or prevent diseases.

    FD&C Act §201(g)(1)(B) [21 U.S.C. §321(g)(1)(B)]
  2. FDA says the products are unapproved new drugs because no FDA-approved application is in effect for them.

    FD&C Act §§505(a), 301(d) [21 U.S.C. §§355(a), 331(d)]
  3. FDA says the products are misbranded because their labeling lacks adequate directions for a layperson to use them safely for the promoted conditions.

    FD&C Act §502(f)(1) [21 U.S.C. §352(f)(1)]
  4. FDA says the CBD products cannot be legally marketed as nonprescription drugs without an approved new drug application.

    FD&C Act §505G [21 U.S.C. §355h]; 21 C.F.R. §330.1(e)
  5. FDA says introducing or delivering misbranded drugs into interstate commerce violates the Act.

    FD&C Act §301(a) [21 U.S.C. §331(a)]
  6. FDA warned that applying non-sterile Frankincense Essential Oil to a newborn's umbilical cord may cause infection.

What FDA wants

FDA asks Young Living to notify it in writing within 15 working days of the specific steps taken to address the violations, prevent recurrence, and include related documentation. If corrective actions cannot be completed in that time, FDA asks the company to explain the delay and state when it will finish.

Who should pay attention

  • retailers and marketplaces that sell Young Living products
  • brands that use consultants or influencers to market health products
  • CBD and essential oil companies making disease-related claims

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk